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stage AD hinders the development of new therapies as it is difficult to prove their clinical relevance.
Methods: We assessed functional changes over three years in 289 elderly memory complainers from
the Investigation of Alzheimer’s Predictors in subjective memory complainers cohort using the Am-
sterdam Instrumental-Activities-of-Daily-Living questionnaire (A-IADL-Q).
Results: No overall functional decline related to AD imaging markers was evidenced. However, five
distinct classes of A-IADL-Q trajectories were identified. The largest class (212 [73.4%]) had stable
A-IADL-Q scores over 3 years. A second group (23 [8.0%]) showed a persistent functional decline,
higher amyloid load (P 5 .0005), and lower education (P 5 .0392).
Discussion: The A-IADL-Q identified a subtle functional decline in asymptomatic at-risk AD indi-
viduals. This could have important implications in the field of early intervention in AD.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Therapeutic trials in Alzheimer’s disease (AD) start
including participants at the earliest clinical stages to pre-
vent the future onset of dementia [1]. Cognitively normal in-onoraria as a speaker or consultant for Eli Lilly, Bio-
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dementia [3–6] may already show subtle functional
changes, that is, changes in the person’s ability to manage
tasks and activities that are usually required in daily life
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(BADLs) and instrumental (IADLs) [7]. BADLs include
fundamental skills that are needed to manage basic physical
needs (personal hygiene, eating, dressing, toileting, conti-
nence). IADLs include activities related to living in commu-
nity, mostly done with forethought, and for which multiple
cognitive processes are needed (e.g., cleaning, washing
clothes, managing medications and finances, driving) [8].
Because IADLs are by definition more complex that
BADLs, they are more vulnerable to early brain pathological
events [9].
There is currently a lack of tools that are sensitive enough
to detect such subtle functional changes in patients with
early-stage AD. Performance in IADLs is often measured
using questionnaires, which are sometimes outdated, not
nuanced enough (answers to questions being “impaired or
not”), or self-report measures, being possibly biased by ano-
sognosia (i.e. loss of insight), which may already be present
in the early stages [6]. To overcome these limitations, Sikkes
et al. [10] developed an informant-based computerized ques-
tionnaire in 2012, the Amsterdam IADL Questionnaire
(A-IADL-Q). The initial version of the A-IADL-Q was an
adaptive 47- to 70-item questionnaire, covering a broad
range of cognitive IADLs, aimed to detect early dementia
and early-onset dementia. The A-IADL-Q short version
has been recently developed and has maintained the psycho-
metric quality of the original version [11]. It consists of 30
items (derived from the original version) that can be used
to detect functional decline from normal aging to dementia.
We used this innovative questionnaire to identify subtle
functional decline in our cohort of individuals with subjec-
tive cognitive decline (SCD) followed up for three years.
In this study, we hypothesized a subtle functional decline
in preclinical AD. In the population of elderly subjective
memory complainers, we expect heterogeneity in the func-
tional trajectories. Using the A-IADL-Q in the Investigation
of Alzheimer’s Predictors in subjectivememory complainers
(INSIGHT-preAD) cohort, we wanted (1) to investigate
whether we can identify subgroups of functional evolution
and, if these subgroups exist, (2) to explore whether func-
tional decline can be characterized by a distinct pattern of
demographic and biological factors.2. Method
2.1. Study design and participants
Participants eligible for this study were included in a lon-
gitudinal observational study, the INSIGHT-preAD study,
which has been described previously [12]. This is an ongoing
single-center study at the Institute of Memory and Alz-
heimer’s disease of the Pitie-Salpe^triere University Hospital
located in Paris, France. The INSIGHT-preAD study was de-
signed to identify risk factors and markers of progression to
AD in asymptomatic at-risk (due to their age and memory
complaints) individuals [12].Three hundred and eighteen participants were recruited
by the neurologists of the memory clinic and through
announcement of the study in the media, and they were
enrolled between May 25, 2013, and January 20, 2015.
The INSIGHT-preAD study has been approved by the ethics
committee of the Pitie-Salpe^triere Hospital, and all partici-
pants provided written informed consent. Participants are
between 70 and 85 years of age with SCD but unimpaired
cognition (Mini–Mental State Examination 27 and
Clinical Dementia Rating Scale 5 0) and without episodic
memory deficit (Free and Cued Selective Reminding Test
[13,14] total recall score 41). To this day, participants
have now been followed up for 3 years out of the 5-year-
long protocol.
A comprehensive cognitive and functional assessment
was performed every 12 months, including Mini–Mental
State Examination, Free and Cued Selective Reminding
Test, Trail Making Test, Frontal Assessment Battery, Verbal
fluency, and A-IADL-Q (this latter filled by the patient’s
study partner).
The brain glucose metabolism was measured with
18F-fluorodeoxyglucose (18F-FDG) positron emission to-
mography (PET) every 24 months. The means of standard-
ized uptake value ratio (SUVr) in four bilateral regions,
specifically affected by AD [15], were used to calculate
cortical metabolic indices: posterior cingulate cortex, infe-
rior parietal lobule, precuneus, and inferior temporal gyrus
(the reference region is the pons) [12].
Brain amyloid load was also measured every 24 months,
by 18F-florbetapir (18F-AV45) PET. In particular, the
18F-AV45 SUVr was calculated by averaging the mean
activity of the following regions of interests (ROIs): left
and right precuneus, cingulum posterior, cingulum anterior
and parietal, temporal, and orbitofrontal cortices (the refer-
ence region is a combination of the whole cerebellum and
pons regions). Then, the threshold set for normal versus
abnormal uptake is 0.7918.
In the present study, relevant data were collected from the
INSIGHT-preAD cohort, including age, gender, level of ed-
ucation, neuropsychological scores, functional autonomy,
level of amyloid deposition, and brain glucose metabolism.
Global amyloid-PET SUVr and FDG-PET mean SUVr in
AD-related ROIs were used as markers of preclinical AD
for amyloid deposition and hypometabolism, respectively.2.2. Amsterdam IADL Questionnaire
The A-IADL-Q is an informant-based questionnaire
covering a broad range of complex IADLs such as house-
hold, administration, work, computer use, leisure time, ap-
pliances, and transport activities. For the present study, the
short version was used, consisting of 30 items [11]. For
each item, difficulty in performance is rated on a 5-point
Likert scale (ranging from “no difficulty in performing this
task” to “no longer able to perform this task”). Scoring is
based on item response theory, a paradigm linking item
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trait score, which is converted to a T-score, with a mean of 50
and SD of 10. This score reflects one’s level of IADL func-
tioning, with higher scores indicating better IADL func-
tioning. The A-IADL-Q was previously found to have a
high test-retest reliability, good content and construct valid-
ity, and able to detect changes over time [16,17].
We collected answers from each A-IADL-Q as reported
by the study partner of every participant. An independent
blinded person entered the answers on an online version of
the questionnaire. We used the short version of A-IADL-Q
because it has the same psychometric quality than the orig-
inal version and it is shorter thus more user friendly/less
burdensome to the informant [11]. Results were compiled
and extracted for each patient and each visit of the 3-year
follow-up (M0, M12, M24, and M36).2.3. Statistical analysis
Subjects with at least two time points of A-IADL-Q score
and with no missing data for amyloid load, glucose meta-
bolism, age, gender, and education were included in the
analysis. Baseline characteristics were compared between
subjects included and excluded in the analysis using the c2
test for categorical variables and the Student’s t-test for
continuous variables.
To evaluate the impact of amyloid load and glucose meta-
bolism on A-IADL-Q scores evolution in 3 years of follow-
up, we first conducted linear mixed-effects model (LMM).
Amyloid load at baseline, glucose metabolism at baseline,
age at baseline, gender, educational level, and visit were
included as fixed effects in the model and participant as a
random effect. We also included interaction between both
PET biomarkers to study their concomitant impact on global
measures of IADL; interaction of each PET biomarker with
visit to evaluate if baseline PET biomarkers impact on IADL
scores was different across time; and interaction between
both PET biomarkers and visit to investigate the different ef-
fects of PET biomarker concomitant impact on IADL scores
across time. Type II likelihood ratio tests were used to test
each fixed effect and interaction. Cohen’s f2 were calculated,
using the marginal R2 [18], for each effect to estimate their
size. Normality of residuals and random effects as well as
heteroskedasticity were checked visually. Influencers and
outliers were checked computing hat values and Cook’s dis-
tance.
As LMMs are restricted to homogeneous population, we
subsequently decided to perform latent class linear mixed
model (LCLMM) [19] to investigate heterogeneous trajec-
tories. Therefore, G latent classes of subjects characterized
by G mean profiles of trajectories were computed. We
compared models from one up to seven classes using
Bayesian information criterion, and we selected the one
which minimize Bayesian information criterion. Mean of
posterior probabilities and percentage of posterior probabil-
ities higher than 0.7 were computed. IADL scores evolutionwas modeled by the interaction between classes and visits.
Using a multinomial logistic model, characteristics of clas-
ses were compared to the class with the largest number of
subjects on amyloid load at baseline, glucose metabolism
at baseline, age at baseline, gender, and educational level.
Normality of residuals and random effects as well as hetero-
skedasticity were checked visually.
Statistical analyses were performed using R 3.5.0. Pack-
ages lme4 (version 1.1-17) and LCMM (version 1.7.9) were
used to perform LMM and LCLMM, respectively.3. Results
As shown in Supplementary Table 1, 289 subjects were
included in the analysis. The 29 excluded subjects were
older, with lower educational level and had lower scores
for Trail Making Test B–A time. However, no statistical dif-
ferences in the A-IADL-Q score at baseline were found. Par-
ticipants were mostly women (61.94%), with a mean age of
75.9 6 3.44 years at baseline and a diploma equivalent of a
high school diploma or higher (69.55%). At baseline, they
had an average Mini–Mental State Examination score of
28.68 6 0.95 and an A-IADL-Q score of 67.01 6 3.66.
LMM results are presented in Table 1. Lower overall
score of A-IADL-Q score, indicating worse IADL func-
tioning, was associated with older age at baseline
(20.16 6 0.06, P 5 .0028) and with higher 18F-AV45
SUVr (226.406 11.53, P5 .0372). Male gender was asso-
ciated with a higher overall A-IADL-Q score (0.97 6 0.39,
P 5 .0128). All three effects had similar impact size (f2:
0.018, 0.015, and 0.011 for age, gender, and amyloid-PET,
respectively). No overall functional decline was found
(P 5 .4904), and impact of amyloid-PET and FDG-PET
did not change over time (P5 .6128 and P5 .5827, respec-
tively). We also investigated the interaction between visit
and age, gender, and educational level, but they were not sig-
nificant (data not shown).
Five groups of A-IADL-Q evolution were identified by
the LCLMM in the INSIGHT-preAD cohort (Fig. 1B and
C). Group 1 (n 5 20; 7% of our cohort) included subjects
with a slight but significant improvement in A-IADL-Q
scores (mainly between M24 and M36). In group 2
(n 5 212, 74%), A-IADL-Q scores were high and stable
over time. A-IADL-Q scores in group 3 (n 5 7; 2%) were
around the pathological threshold for clinical diagnosis of
dementia (51.4; [20]). Their overall average trajectory had
slightly diminished over time, with a fluctuating trend.
Group 4 (n 5 23; 8%) showed a persistent decline over
time in A-IADL-Q scores. In group 5 (n 5 27; 9%), A-
IADL-Q scores were initially lower than in group 2 and
then statistically improved on average over time, with a
peak at M24 and a slight decrease at M36.
We compared characteristics of groups 1, 3, 4, and 5 with
that of group 2. This latter group was chosen as a reference
because of its highest and stable values of A-IADL-Q
(Table 2, Fig. 2). Individuals included in group 4 had a
Table 1
Linear mixed effects model (LMM) results on Amsterdam IADL score
Variables Coefficient 6 SEy Cohen’s f2
P
value
Age at baseline 20.16 6 0.06 .018 .0028*
Gender (M) 0.97 6 0.39 .015 .0128*
Educational level (low) 0.16 6 0.41 ,.001 .7008
Amyloid-PET 226.40 6 11.53 .011 .0372*
FDG-PET 27.16 6 3.83 .002 .5421
Visit .002 .4904
M12 28.00 6 9.44
M24 20.22 6 9.55
M36 215.00 6 9.90
Visit:PET-amyloid .001 .6128
M12 10.62 6 11.73
M24 3.41 6 11.91
M36 19.34 6 12.45
Visit:PET-FDG .001 .5827
M12 3.28 6 3.91
M24 0.45 6 3.94
M36 6.14 6 4.09
PET-amyloid:PET-FDG 10.22 6 4.80 .008 .0711
Visit:PET-amyloid:PET-FDG ,.001 .4439
M12 24.36 6 4.90
M24 22.02 6 4.95
M36 28.02 6 5.19
NOTE. Coefficients and standard error (SE) were extracted from com-
plete GLMs with all interactions.
Abbreviations: OR, odd ratio; SE, standard errors.
*P , .05.
yFor the following effect, the reference categories were: gender: women;
educational level: high; visit: M0.
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lower level of education (OR 5 2.66 6 1.26, P 5 .0392),
compared with the reference group (Fig. 2). In group 5, sub-
jects were less likely to be men (OR 5 0.36 6 0.18,
P 5 .0428), had higher amyloid load
(OR 5 18.91 6 18.25, P 5 .0023), and lower brain meta-
bolism on FDG-PET (OR 5 0.14 6 0.13, P 5 .0383).
Among the participants of the INSIGHT-preAD cohort
(n 5 6) who cognitively declined and were clinically diag-
nosed with prodromal AD within the 3 years of follow-up,
4 (1.9% of group) were in group 2 and 2 (8.7% of group)
in group 4.4. Discussion
In this longitudinal observational study, we aimed at
exploring functional changes in individuals at risk of devel-
oping AD, due to their age, cognitive complaints, and in a
part of the subjects, brain amyloid positivity. We chose to
use the A-IADL-Q to assess functional status because it is
shown to be valid and reliable and to correlate longitudinally
with cognitive decline, which underlines its ability to detect
changes over time [16]. It has been used to identify AD-
related functional decline and have been validated in
different countries [10,21]. This explains its growing
use in research (e.g., ClinicalTrials.gov Identifier:NCT03980730 and NCT03174886). To investigate
functional decline in our cohort of subjective memory
complainers, we initially performed an LMM. First, we
found a negative association between A-IADL-Q and age,
which was expected since functional decline and
progressive reduction of autonomy is a condition known to
be associated with growing age. Elderly people appear to
be more vulnerable because of the effects of biological or
psychological aging: a slight function loss is commonly
present in normal aging, whereas function loss patterns
that imply a progressively greater disability may be driven
by causes other than age, such as a neurodegenerative
disease [22,23]. Second, participants with poorer
performances in IADLs also had higher brain amyloid
burden. This result is particularly interesting if we
consider that our sample included cognitively healthy
individuals with an SCD, who were potentially in the
preclinical phase of AD (“asymptomatic at-risk individuals”
according to [24]). The literature about the relationship be-
tween amyloid deposition and loss of function in predemen-
tia stages of AD is still rather scarce. As an example,
Lilamand et al. [25] found that the presence of amyloid pla-
ques was associated with lower functional ability, in both in-
dividuals with prodromal AD and cognitively normal,
consistently with the present study. This suggests that func-
tional impairment could be one of the first consequences of
AD neuropathology, therefore representing a potential
marker for early-stage AD. Third, male gender was associ-
ated with higher ability in IADLs, consistently with previous
studies showing that women generally encounter a greater
functional impairment than men [26,27]. This gender
difference could be linked to the use of different strategies
to perform IADLs between men and women [28]. For
instance, gender-specific navigational strategies have been
evidenced in AD [29], which can in turn have an impact
on IADLs such as driving. Moreover, sociocultural issues
may also have a role, due to the historically gendered divi-
sion of household labor, especially for individuals who are
now in old age. Indeed, in a recent model, the (simply)
greater exposure to IADLs (due to sociocultural expecta-
tions, physical health, and socioeconomic factors, among
others) is seen to be responsible for cognitive and physical
improvements (called functional reserve), which in turn
delay the onset of functional disability [30]. However, we
must also consider that A-IADL-Q was developed to specif-
ically address the need of a measurement tool free from
gender-based issues, and other studies found no relationship
between this score and gender [17]. Also, an additional
explanation is that women in our cohort may be suffering
from more pathological conditions, such as arthritis, osteo-
porosis, high blood pressure, and cataracts, which generally
affect women more than men and which are known to reduce
the ability to perform IADLs [31]. Finally, the LMM showed
no overall change in A-IADL-Q scores over the 3 years. Our
3-year-long follow-up may have been too short to observe a
clear decline in IADLs, considering that our cohort includes
Fig. 1. (A) Individual evolution of the A-IADL-Q scores in the 289 INSIGHT-preAD cohort participants over three years. (B) The five mean A-IADL-Q tra-
jectories identified by the LCLMM. (C) Individuals’ A-IADL-Q trajectory according to the group of evolution identified by the LCLMM [Group 1: n 5 20
(6.9%); Group 2: n5 212 (73.4%); Group 3: n5 7 (2.4%); Group 4: n5 23 (8.0%); Group 5: n5 27 (9.3%)]. Abbreviations: A-IADL-Q, Amsterdam Instru-
mental Activities of Daily Living Questionnaire; INSIGHT-preAD, Investigation of Alzheimer’s Predictors in subjective memory complainers; LCLMM, latent
class linear mixed model.
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may not be sensitive enough to detect subtle changes in
IADLs (which has been previously demonstrated), an addi-
tional and plausible explanation may be that our sample is
not homogeneous enough to detect clear longitudinal
changes on average. In fact, asymptomatic at-risk individ-
uals with SCD represent a highly heterogeneous population
(as shown in Fig. 1A), and for this reason, we have chosen to
also perform an LCLMM, which seems to be a more appro-Table 2
Comparison between each group and group 2 (reference group)
Classes
Age at baseline
Gender
(reference:women)
Educationa
(reference:
OR 6 SE P value OR 6 SE P value OR 6 SE
Class 1 1.05 6 0.07 .5035 0.45 6 0.25 .1464 0.93 6 0.4
Class 3 1.18 6 0.13 .1314 0.45 6 0.41 .3777 0.35 6 0.3
Class 4 1.10 6 0.08 .1722 0.55 6 0.29 .2532 2.66 6 1.2
Class 5 1.12 6 0.07 .0723 0.36 6 0.18 .0428* 0.71 6 0.3
Abbreviations: OR, odd ratio; SE, standard errors.
*P , .05.priate approach for our purpose. LCLMM identifies groups
of subjects on the basis of a given criterion (here, perfor-
mance on IADLs over the 3 years) and then compares
them to a reference group. In this way, it allows to study sub-
populations or latent classes. In the present study, the
LCLMM identified five latent classes and tended to model
the largest one (group 2) over the others. Thanks to the par-
titioning in subpopulations, we have been able to explore
which factors were associated with the longitudinall level
high) PET-amyloid at baseline PET-FDG at baseline
P value OR 6 SE P value OR 6 SE P value
8 .8899 1.34 6 1.99 .8440 0.79 6 0.76 .8106
8 .3397 0.29 6 0.89 .6874 0.60 6 0.98 .7542
6 .0392* 33.86 6 34.26 .0005* 0.69 6 0.65 .6986
5 .4809 18.91 6 18.25 .0023* 0.14 6 0.13 .0383*
w
e
b
4
C
/F
P
O
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consistently high IADL skills over the follow-up (group 2,
74% of the sample) included 4 of the 6 converters of our co-
horts. These were participants with SCD and normal cogni-
tion at baseline, who progressed to prodromal AD during the
follow-up. This finding confirmed that a functional deterio-
ration is not a mandatory criterion for the diagnosis of pro-
dromal AD [24] because the performance on IADL of
patients at the prodromal stage was comparable with that
of cognitively normal elderly. About 10% of our cohort
experienced an either fluctuating (group 3) or persistent
(group 4) worsening in IADLs. Those with fluctuating diffi-
culties were entirely comparable with our reference group
with stable IADL performance, whereas those with progres-
sive functional decline had a lower level of education, a
greater amyloid load, and 2 of the 6 converters in our cohort
were part of this group. Thus, this group could represent a
subpopulation of elderly individuals with a relatively lower
educational level (and therefore less cognitive reserve and
compensation capacity), where a higher amyloid deposition
affects IADLs before cognitive functioning (except for two
of 20 subjects belonging to this group who also presented
overt cognitive deficits at follow-up testing). An interesting
and a somewhat unexpected finding of this study is that sub-
jects with amyloid deposition and a persistent functional
decline did not show lower brain glucose metabolism. We
did expect functional decline to be more directly associated
with hypometabolism than with amyloid deposition [32].
Probably, the progressive decline in performing IADLs in
this group was associated with a lower metabolism in
ROIs that are not AD-related (for example in the frontal
lobe) and therefore not explored here. In addition, a part of
our cohort (about 16%; groups 1 and 5) showed a statistically
significant improvement in IADL performance during the
follow-up, with two different trajectories (see Fig. 1C). A
similar trend has been previously demonstrated in studies
in which elderly with more or less marked functional deteri-
oration regained some degree of independence. The reason
behind this recovery is not yet known, but it has been pro-
posed to lie in a higher level of resilience [33]. In particular,
the subjects who experienced a slight improvement in per-
formance mainly between M24 and M36 (group 1) were
entirely comparable to our reference group with stable
IADLs. On the contrary, those who improved in IADLs,
eventually encountering a decline from M24 to M36, were
proportionately more men and had a greater amyloid load
and less brain glucose metabolism. We propose that this
group includes subjects with an underlying AD pathology
who are in a compensatory phase, in which they show no
cognitive or functional impairment, thanks to a high levelFig. 2. Estimated marginal probabilities of class belonging using a multinomial log
3 years according to (A) gender status, (B) educational level, (C) age at baseline,
breviations: A-IADL-Q, Amsterdam Instrumental Activities of Daily Living Que
phy; SUVr, standardized uptake value ratio.of cognitive reserve and resilience. The slight decline
observed between M24 and M36 could represent the begin-
ning of a process of decompensation. This hypothesis would
be consistent with a previous study on the INSIGHT-preAD
cohort that analyzed data from the first 2 years of follow-up
[12]. Our group failed to detect overall cognitive changes
and discussed this finding as the result of a compensation
mechanism mediated by the frontal lobe, where at-rest a os-
cillations on EEG were increased.5. Conclusion
To conclude, the present study showed that slight changes
in IADLs may be already present in very early, mostly “pre-
clinical,” AD which might be useful to inform about poten-
tial future onset of AD dementia, contrary to current leading
models of disease progression. The A-IADL-Q appears to be
a good tool to use in the predementia phases to detect this
subtle functional decline.
However, we should better understand if a functional
measure has sufficient sensitivity and specificity to consti-
tute an endpoint of studies on the progression from preclin-
ical to clinical. Our study is data-driven and explorative and
needs replication in larger samples. Thus, the implementa-
tion of the A-IADL-Q in large cohorts of individuals at
risk for AD such as the European Prevention on Alzheimer’s
Dementia [34,35] cohort could help in disentangling this
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design, data collection, data analysis, or data interpretation.istic model. Group 2 is the reference class with stable A-IADL-Q scores over
(D) amyloid-PET SUVr, and (E) FDG-PET SUVr in AD-related ROIs. Ab-
stionnaire; FDG, 18F-fluorodeoxyglucose; PET, positron emission tomogra-
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10.1016/j.trci.2019.08.009.RESEARCH IN CONTEXT
1. Systematic review: We did not find any publication
pertaining specifically to functional decline in pre-
clinical Alzheimer’s disease. There are, however,
many studies describing a subtle cognitive decline
in the preclinical stage of the disease, which would
support such functional changes.
2. Interpretation: In a longitudinal cohort study of 318
elderly memory complainers, we identified a group
of participants with persistent functional decline on
the Amsterdam Instrumental-Activities-of-Daily-
Living questionnaire. This group displayed higher
amyloid load on positron emission tomography and
had a lower education level compared with a control
group with stable functional scores.
3. Future directions: The Amsterdam Instrumental-
Activities-of-Daily-Living questionnaire could be
used in the fields of early detection and intervention
in Alzheimer’s disease.References
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